Chan Heng Fai Ambrose - 28 Dec 2023 Form 4 Insider Report for DSS, INC. (DSS)

Role: Director, 10%+ Owner
Signature: /s/ Heng Fai Ambrose Chan
Issuer symbol: DSS
Transactions as of: 28 Dec 2023
Net transactions value: +$98,137
Form type: 4
Filing time: 02 Jan 2024, 09:10:36 UTC
Previous filing: 19 Dec 2023
Next filing: 11 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DSS	Common Stock	Purchase	$98,137	+672,173	+3.6%	$0.1460	19,586,499	28 Dec 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 28, 2023, the reporting person purchased 672,173 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1239 to $0.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2	The beneficial ownership of Heng Fai Chan includes a total of 82,458,315 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 19,586,499 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 21,366,177 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited.

Content

On December 28, 2023, the reporting person purchased 672,173 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1239 to $0.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

The beneficial ownership of Heng Fai Chan includes a total of 82,458,315 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 19,586,499 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 21,366,177 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited.